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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human
peripheral blood and cancer
Mary Anna Venneri,1,2 Michele De Palma,1,2 Maurilio Ponzoni,3 Ferdinando Pucci,1,2,4 Cristina Scielzo,5 Erika Zonari,1,2
Roberta Mazzieri,1,2 Claudio Doglioni,3 and Luigi Naldini1,2,4
1Angiogenesis and Tumour Targeting Research Unit, 2San Raffaele Telethon Institute for Gene Therapy, 3Department of Pathology, 4Vita-Salute San Raffaele
University, and 5Department of Oncology, San Raffaele Scientific Institute, Milan, Italy
Tumor-infiltrating myeloid cells, includ-
ing tumor-associated macrophages
(TAMs), have been implicated in tumor
progression. We recently described a lin-
eage of mouse monocytes characterized
by expression of the Tie2 angiopoietin
receptor and required for the vasculariza-
tion and growth of several tumor models.
Here, we report that TIE2 expression in
human blood identifies a subset of mono-
cytes distinct from classical inflamma-
tory monocytes and comprised within the
less abundant “resident” population.
These TIE2-expressing monocytes (TEMs)
accounted for 2% to 7% of blood mono-
nuclear cells in healthy donors and were
distinct from rare circulating endothelial
cells and progenitors. In human cancer
patients, TEMs were observed in the blood
and, intriguingly, within the tumors, where
they represented the main monocyte
population distinct from TAMs. Con-
versely, TEMs were hardly detected in
nonneoplastic tissues. In vitro, TEMs mi-
grated toward angiopoietin-2, a TIE2 li-
gand released by activated endothelial
cells and angiogenic vessels, suggesting
a homing mechanism for TEMs to tumors.
Purified human TEMs, but not TEM-de-
pleted monocytes, markedly promoted an-
giogenesis in xenotransplanted human
tumors, suggesting a potentially critical
role of TEMs in human cancer progres-
sion. Human TEMs may provide a novel,
biologically relevant marker of angiogen-
esis and represent a previously unrecog-
nized target of cancer therapy. (Blood.
2007;109:5276-5285)
© 2007 by The American Society of Hematology
Introduction
Hematopoietic cells of diverse lineages contribute to tumor progres-
sion.1-7 Among these cells, tumor-associated macrophages (TAMs)
play important roles in tumorigenesis.3,8-10 TAMs derive from
circulating monocytes, which differentiate into macrophages upon
homing to tumors. In tumors, TAMs play dichotomous functions.
Although TAMs may exert direct antitumor activities,11,12 increas-
ing data indicate that they are skewed by the tumor microenviron-
ment to a protumoral phenotype.8,13 Indeed, TAMs can blunt
antitumor immunity and stimulate angiogenesis, cell migration,
invasion, and metastasis.3,9 Whereas the divergent TAM functions
(ie, antitumoral and protumoral activities) are thought to be
contextually modulated by the tumor microenvironment,8 emerg-
ing data suggest that distinct subsets of circulating monocytes exist
that are committed to specific functions, including tissue remodel-
ing and proangiogenic activity.14-16 In this regard, we recently
identified in mouse tumor models a subset of tumor-infiltrating
monocytes characterized by the expression of the angiopoietin
receptor Tie2/Tek,15,17 a molecule previously known to be restricted
to endothelial and hematopoietic stem cells.18,19 In mice, Tie2-
expressing monocytes (TEMs) home to tumors, where they are
required for angiogenesis. Indeed, selective elimination of TEMs
by a suicide gene strategy prevented angiogenesis and induced
tumor regression.15,17 In these tumor models, angiogenesis was
inhibited despite the fact that TAM recruitment to tumors was not
impaired, indicating that a specific subset of myeloid-lineage cells
was primarily responsible for promoting angiogenesis. This con-
cept has received support from other studies that reported proangio-
genic activity of selected myeloid cell subsets in mouse tumors,
including VEGFR-1CD11b myeloid cells, Gr-1CD11b myeloid
suppressor cells, and CD11cMHC-II dendritic cell precursors.20-26
However, because most of the cell-surface markers used to identify
these cell subsets are broadly expressed among myeloid cells, it is
unclear whether these cell populations represent distinct rather than
overlapping proangiogenic myeloid cells, possibly comprising the
TEMs.7 Inhibiting the activities of proangiogenic myeloid cells should
represent a valuable anticancer strategy. Yet, the rationale for this
approach would obtain major support from the identification and
functional characterization of proangiogenic myeloid cells in humans.
Here, we report that TIE2 expression in human peripheral blood
(PB) identifies a novel subset of monocytes endowed with marked
proangiogenic activity. These cells are distinct from classic inflam-
matory monocytes, express functional TIE2 receptor, and directly
respond to angiopoietin-2 (Ang-2), a TIE2 ligand up-regulated in
activated and angiogenic blood vessels. Interestingly, human TEMs
are preferentially recruited to tumors, where they constitute the
pre-eminent monocyte population distinct from TAMs
Our results suggest a potential critical role of TEMs in human
cancer angiogenesis and progression. These cells may provide a
biologically relevant readout to monitor angiogenesis and may
represent previously unrecognized targets of anticancer therapies.
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Materials and methods
Cell purification and cell sorting
PB was obtained from healthy volunteers following informed consent,
according to the Declaration of Helsinki and a protocol approved by the
H. San Raffaele Bioethical Committee. Total leukocytes were analyzed
after lysis of erythrocytes using ammonium chloride. Peripheral blood
mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque gradi-
ent. Granulocytes and T and B lymphocytes were positively selected by
magnetic sorting (using CD15, CD3, or CD19 MicroBeads, respec-
tively; Miltenyi, Bergisch Gladbach, Germany). T-cell–depleted PBMCs
were negatively selected by CD3 MicroBeads. Resident monocytes
(CD16CD14low) were enriched from PBMCs by negative selection of
T, B, and natural killer (NK) cells (using a cocktail of CD3, CD19, and
CD56 MicroBeads), followed by positive selection by CD16 Mi-
croBeads. Inflammatory monocytes (CD16CD14) were enriched by
negative selection of CD16 cells, followed by positive selection by
CD14 MicroBeads. For cell sorting, we used a Becton Dickinson
(Heidelberg, Germany) FACS Vantage SE-FACSDiVa equipped with
Argon Ion and HeNe lasers and the Quadra-Sort option. Sorted
populations included CD14TIE2, CD14TIE2, and CD14 mono-
cytes (using FITC-conjugated anti-CD14 and PE-conjugated anti-TIE2
antibodies) and CD14CD16 and CD14CD16 monocytes (using
FITC-conjugated anti-CD14, PC5-conjugated anti-CD16, and PE-
conjugated anti-TIE2 antibodies).
Flow cytometry and antibodies
Blood cells and tumors reduced to single-cell suspensions by collagenase
digestion15 were processed for flow cytometry as follows. Cells were
blocked in 1% bovine serum albumin (BSA) in phosphate-buffered saline
(PBS) containing the FcR Blocking Reagent (Miltenyi). After blocking, the
Fc-blocked cells (106 cells) were stained with the following monoclonal
antibodies (1-5 g/mL): PE-conjugated anti-TIE2 (clone 83715), IgG1
isotypic control (clone IC002P), and anti-CCR2 from R&D Systems
(Minneapolis, MN); PE-conjugated anti-CD19, anti-CD4, and IgG1 iso-
typic control (clone 11711) from BD Pharmingen (Heidelberg, Germany);
PE-conjugated anti-CD133 (clone AC133) from Miltenyi; PE-conjugated
anti-CD146 (clone S-endo1) from Biocytex (Marseille, France); FITC-
conjugated anti–M-CSFR from R&D Systems; FITC-conjugated anti-
CD62L, anti-CD31, anti-CD16, anti-CD14 from BD Pharmingen; FITC-
conjugated anti-CD11c from Caltag (Burlingame, CA); FITC-conjugated
anti-CD33 from ImmunoTools (Friesoythe, Germany); FITC-conjugated
anti-CD13 from eBioscience (San Diego, CA); APC-conjugated anti-TIE2
(clone 83715) and anti–VEGFR-2 (clone 89106) from R&D Systems;
APC-conjugated anti-CD45, anti-CD14, anti-CD11b, anti-CD3 from BD
Pharmingen; PE-Cy7–conjugated anti-CCR5 from BD Pharmingen; PC5-
conjugated anti-CD56 and anti-CD16 from Beckman Coulter (Hialeah,
FL). All samples were analyzed by a FC500 flow cytometer (Coulter).
Frequency of marker-positive cells is expressed as mean  standard
deviation (SD).
Real-time PCR
Total RNA was extracted from 1  105 to 5  105 cells using the RNeasy
Micro kit (Qiagen, Hilden, Germany) and retrotranscribed using the
superscript III First-Strand kit (Invitrogen, Carlsbad, CA). Taqman analysis
of TIE2, VEGFR2, and GAPDH was performed on RNAse-treated cDNA
using premade Taqman Gene Expression Assays from Applied Biosystems
(Foster City, CA). Analyses were performed in 3 technical replicates, for 40
cycles in standard mode using an ABI7900HT apparatus. The SDS 2.2.1
software (Applied Biosystems) was used to analyze the data. The difference
between the threshold cycle (Ct) of the TIE2 or VEGFR2 transcript and that
of the endogenous control GAPDH (Ct) was used to determine gene
expression. The average Ct of GAPDH was approximately 16 to 18 in both
hematopoietic cells and human umbilical vein endothelial cells (HUVECs).
Ct values are expressed as mean  standard error. To obtain relative
quantification values, we calculated the fold-change of each target mRNA
over its content in a cell population taken as reference from the difference
between the Ct of the target mRNA in the population of interest and the
Ct of the target mRNA in the reference population (Ct) by the formula
2Ct. For each relative value, an interval of confidence (P  .05) was
calculated by the SDS 2.1.1 software; confidence intervals that did not
overlap indicated statistically significant differences (P 	 .05).
Western-blot analysis
Fluorescence-activated cell sorter (FACS)–sorted cells (106) were lysed in
Laemmli buffer, analyzed by 8% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis (SDS-PAGE), transferred on nitrocellulose, incubated
for 2 hours with rabbit anti-TIE2 (1:200; Santa Cruz Biotechnology, Santa
Cruz, CA) or mouse anti-
 actin (1:5000; Sigma-Aldrich, St Louis, MO)
antibodies, and revealed by goat anti–rabbit or antimouse HRP-conjugated
antibodies (Upstate Biotechnology, Lake Placid, NY), followed by ECL
plus (Amersham Bioscience, Freiburg, Germany) reaction and film expo-
sures. For TIE2 immunoprecipitation, 107 cells were lysed with RIPA lysis
buffer and incubated overnight with anti-TIE2 antibodies (Santa Cruz
Biotechnology) and protein G microbeads (Miltenyi). Immunoprecipitated
proteins were purified on separation columns (Miltenyi). Blots were
incubated for 2 hours with a mouse monoclonal HRP-conjugated antiphos-
photyrosine antibody (1:1000; Upstate Biotechnology).
Immunohistochemistry, immunofluorescence, and
confocal analysis
Tissue specimens were obtained from surgical resections following in-
formed consent according to the Declaration of Helsinki and the H. San
Raffaele Bioethical Committee. Samples were embedded in OCT com-
pound and snap-frozen. Five-micrometer sections were fixed in 4%
paraformaldehyde for 15 minutes and immunostained. Briefly, sections
were incubated with anti-TIE2 antibodies followed by detection with a
polymeric labeling 2-step method (Super sensitive ihc detection system;
Biogenex, San Ramon, CA) using 3,3-diaminobenzidine as chromogen.
After screening a panel of commercially available anti-TIE2 antibodies, 2
monoclonals, clone AB33 (Upstate Biotechnology; 1:200 dilution) and
clone TEK9 (Reliatech, Braunschweig, Germany; 1:100 dilution), were
chosen based on their specific and efficient staining of blood vessels and
used with similar results. After immunostaining, the sections were counter-
stained with hematoxylin and eosin.
For immunofluorescence staining, frozen sections were blocked with
1% BSA and 5% fetal bovine serum (FBS). Sections were then stained with
the following antibodies: goat polyclonal anti-TIE2 (R&D Systems) and
monoclonal anti-TIE2 (clone AB33; Upstate Biotechnology) antibodies
followed by donkey anti–goat or goat anti–mouse AlexaFluor 546–
conjugated antibodies (Molecular Probes, Eugene, OR), respectively. To
stain ECs and hematopoietic cells, the following antibodies were used:
rabbit polyclonal anti–von Willebrand factor (DAKO, Carpinteria, CA)
followed by AlexaFluor 488–conjugated antirabbit antibodies (Molecular
Probes); FITC-conjugated anti-CD31, anti-CD13, anti-CD16, anti-CD14
monoclonal antibodies; or APC-conjugated anti-CD45, anti-CD34, anti-
CD11b, anti-CD14 monoclonal antibodies (all from BD Pharmingen).
Immunohistochemistry images (Figure 5) were taken using an Axioskop 2
plus direct microscope (Zeiss, Oberkochen, Germany). Images were
captured by using the AxioCam HRc system and Axiovision 3.1 version 4.4
software (Zeiss). Confocal microscopy (Figure 6) used an Axioskop 2 plus
direct microscope (Zeiss) equipped with a Radiance 2100 three-laser
confocal device (BioRad, Segrate, Italy). Fluorescent signals from the
individual fluorophores were sequentially acquired from single optical
sections and analyzed by Paint Shop Pro X (Corel, Ottawa, Canada).
Axioskop 2 microscope used Zeiss W-PI 10/0.23 or Zeiss Plan-Neofluor
20/0.5 numerical aperture objective lens.
Migration assays
Migration assays were performed in a 24-well transwell containing 8-m
pore-size inserts (Corning, Corning, NY) coated with Basement Membrane
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Extract Cultrex (Trevigen, Gaithersburg, MD). Chemoattractants were
placed in serum-free DMEM medium (600 L) in the bottom compartment
of the chamber, and 100 L of cell suspension (106 cells/mL) was added to
the top compartment. The chambers were incubated at 37°C in humidified
air with 5% CO2 for 12 hours. Migrated cells were labeled with 5 g/mL
calcein-AM (Molecular Probes) in DMEM at 37°C for 1 hour and counted
under a fluorescence microscope. Results are expressed as mean SD from
3 technical replicates. Number of cells migrated in the absence of
chemoattractant (ie, medium) was used as a reference value and set to
100%. Ten percent FBS was used as positive control. Neutralizing
anti-TIE2 antibodies (R&D Systems) were preincubated with cells for 20
minutes at 37°C. Purified goat anti–human IgGs were from Caltag. Ang-2
(R&D Systems) was heat inactivated for 30 minutes at 95°C.
In vivo tumor angiogenesis assays
FACS-sorted cells were coinjected together with U87 human glioma cells in
2 ratios: 1:20 (2.5  105 sorted cells together with 5  106 tumor cells) and
1:100 (5  104 sorted cells together with 5  106 tumor cells), subcutane-
ously in nude mice, and tumors were grown for 5 (1:20 ratio experiment) or
7 (1:100 ratio experiment) days. To quantify angiogenesis, serial sections
spanning the whole tumor were cut for each 1 of 3 tumors per group and
immunostained for CD31 (rat anti–mouse CD31 [BD Pharmingen], fol-
lowed by goat anti–rat AlexaFluor 546–conjugated antibodies [Molecular
Probes]). The total tumor area in every fifth section was scanned at  100
magnification by a confocal microscope. We then measured the vascular
area on individual confocal planes by computer-assisted digital image
analysis.27 Counts were averaged to obtain the vascular area, and values
are expressed as mean  SD. Statistical significance was calculated by
Student t test.
Results
TIE2 expression in human peripheral blood identifies a subset
of CD14 monocytes
In order to investigate TIE2 expression by human hematopoietic
cells, we stained peripheral blood (PB) leukocytes obtained from
healthy donors with a mouse anti–human TIE2 monoclonal anti-
body (clone 83715; R&D Systems) and analyzed the cells by flow
cytometry. A significant fraction of monocytes, but not granulo-
cytes or lymphocytes identified on the basis of physical gating,
were TIE2 (Figure 1A). TIE2 cells accounted for 1.6% to 7.4%
(mean: 3.3%  1.5%; n  16) of the total PB mononuclear cells
(PBMCs) and expressed CD14 (Figure 1B), which is a compo-
nent of the lipopolysaccharide receptor broadly expressed by
human monocytes.16
Circulating endothelial cells (CECs) and endothelial progenitor
cells (EPCs) can be detected at very low frequency in PB and are
expected to express TIE2.28 The relatively high frequency of the
TIE2 cells and the fact that these cells express monocyte markers
(see paragraph below) would, in principle, be sufficient to exclude
that they represent CECs/EPCs. However, to formally rule out this
possibility, we stained PBMCs with monoclonal antibodies di-
rected against VEGFR-2, AC133, and CD146, which have been
previously used to identify CECs/EPCs.28-30 We found that the vast
majority of the PB TIE2 cells were AC133, CD146 (Figure
1C), and VEGFR-2 (Figure 1D), further indicating that they were
distinct from circulating CECs/EPCs. We noted, however, that a
small fraction (1%-2%) of the TIE2 cells were CD14VEGFR-
2, a phenotype previously associated with monocytes endowed
with endothelial-like differentiation capacity.31
Recent studies have suggested that human CD14 monocytes
can be divided into 2 main subsets according to the expression of
CD16, a Fc gamma receptor III.14 CD14highCD16 cells are the
most abundant monocytes in PB and are thought to represent
classical monocytes that mediate inflammatory responses (“inflam-
matory” monocytes), whereas CD14lowCD16 cells are a less-
characterized subset that are thought to represent the precursors of
tissue-resident macrophages and are referred to as “resident”
monocytes.14,16 Interestingly, we found that TIE2 cells were
comprised within CD14lowCD16 monocytes and were mostly
excluded from the CD14highCD16 subset (Figure 1E). In different
samples (n  10), analyzed either by multi-color flow cytometry
(Figure 1E) or after FACS sorting of the 2 monocyte subsets
(Figure 1F), TIE2 cells accounted for 35% to 75% of the
CD14lowCD16 monocytes. These results indicated that TIE2
expression in PB specifically identified a subset of CD16 mono-
cytes distinct from common inflammatory monocytes.
In order to verify TIE2 expression at the transcriptional level,
we performed real-time PCR of TIE2 mRNA on FACS-sorted
CD14TIE2 TEMs and on CD14lowCD16 resident and
CD14CD16 inflammatory monocytes, using GAPDH as internal
standard (Figure 2A-B). The TIE2 transcript was clearly expressed
in CD14lowCD16 resident but nearly undetectable in CD14CD16
inflammatory monocytes, and it was significantly enriched (8-fold)
in CD14TIE2 TEMs compared with the resident monocytes.
However, TIE2 mRNA expression in TEMs was much lower than
in human endothelial cells (HUVECs), used as positive control
(Ct  6.1  0.6; n  2). Of note, the VEGFR2 transcript, which
was expressed in HUVECs to a similar level as TIE2 (Ct  5.8),
was expressed to a much lower level than TIE2 in resident
monocytes and TEMs. These results argue against the possibil-
ity that low-level contamination of the TIE2 cell fraction by
CECs/EPCs was responsible for the recovery of the TIE2 signal
from monocytes.
We then analyzed TIE2 receptor expression by Western-blot
analysis of sorted hematopoietic populations using antibodies
directed against the C-terminus of the TIE2 protein. As shown in
Figure 2C, a band with the expected 145-kDa molecular weight of
the TIE2 protein and comigrating with a major band in HUVECs
was clearly detectable only in lysates of FACS-sorted CD14TIE2
cells and barely detectable in total PBMCs, among all blood cell
subsets analyzed. TIE2 was auto-phosphorylated on tyrosine, as
shown by immunoprecipitation from magnetically sorted resident
monocytes and immunostaining with antiphosphotyrosine antibod-
ies, indicating functional activation of the receptor in these cells
(Figure 2D).
We further investigated the phenotype of circulating TIE2
cells (Figure 3) and found that they were CD45, CD11b (MAC-
1), CD11c, CCR2, CCR5, and L-selectin (CD62L), a
surface profile that has been previously associated with resident
monocytes.16 TIE2 cells did not express the natural killer cell
marker CD56 or, as expected, the lymphocyte-specific markers
CD3 (T cells) and CD19 (B cells), whereas they expressed a low
level of CD4, a T-lymphocyte coreceptor also expressed by
monocytes. The TIE2 cells homogeneously expressed CD33
(sialic-acid binding Ig-like lectin 3, a sialoadhesion integrin highly
expressed by monocytes32), the macrophage-colony stimulating
factor receptor (M-CSFR; also known as c-FMS or CD115, a
chemokine receptor involved in the recruitment of monocytes to
tumors33), and CD13 (aminopeptidase N, a myeloid marker34).
Interestingly, expression of these markers has also been associated
with an immature or progenitor cell phenotype.35
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TIE2-expressing monocytes are recruited to human tumors
The analysis of blood samples obtained from 7 cancer patients at
the time of surgery demonstrated in all cases the presence of TIE2
monocytes with a surface phenotype similar to that of TEMs from
healthy donors. In the patients, the frequency of TEMs ranged from
1.8% to 10.1% (mean: 4.9%  3.0%) of the total PBMCs. Further
studies are required to assess whether TEM frequency in cancer
patients significantly differs from the normal range and correlates
with clinical parameters.
To study whether human TIE2 monocytes are present in
human solid tumors, we analyzed the hematopoietic infiltrate of 21
human cancer specimens, including kidney, colorectal, breast,
gastric, pancreatic, and lung carcinomas, and soft tissue sarcomas,
by 4-color flow cytometry analysis, immunohistochemistry, and
confocal immunofluorescence microscopy (Table S1, available on
the Blood website; see the Supplemental Materials link at the top of
the online article).
Fresh tumor tissues obtained from surgical resections were
made into single-cell suspensions and analyzed by flow cytometry
for the expression of (i) the pan-leukocyte marker CD45, (ii) the
monocyte markers CD14 or CD11b, (iii) the EC markers CD31 or
CD34, and (iv) TIE2 (Figure 4). Where possible, a sample of
nonneoplastic tissue adjacent to the tumor was also obtained for
comparative analysis. As expected, in all tumors analyzed (n  9),
the vast majority of ECs, defined as CD31CD45 or CD34CD45,
expressed TIE2 (Figure 4A-B). In addition to ECs, we noted that a small
fraction (1%-12%) of the total CD45CD31/low tumor–derived leuko-
cytes expressed TIE2 (Figure 4B). Interestingly, these TIE2CD45
cells were highly enriched in the CD14 population (37%-72% TIE2,
n 7), which is a small fraction of the hematopoietic infiltrate and
Figure 1. A subset of human monocytes express the
TIE2 angiopoietin receptor. (A) Flow cytometry analysis
of PB granulocytes (G), lymphocytes (L), and monocytes
(M) identified on the basis of physical gating (dot plot on
the left; gates indicated by dashed line) shows TIE2
expression in a subset of monocytes (open red line in the
histogram plots on the right; filled line IgG isotype con-
trol). Percentages of marker-positive cells are indicated.
(B) The TIE2 PBMCs (red gate in left panels) are mostly
CD14 monocytes (dot plots on the right). Representa-
tive analysis of at least 16 performed on different donors.
(C) The vast majority of TIE2 PBMCs do not express the
CEC/EPC markers AC133 or CD146. Rare TIE2AC133
and TIE2CD146 cells may represent EPCs and CECs,
respectively. Similar findings were obtained on 2 different
PBMC samples. (D) A small subset of TIE2 cells are
VEGFR-2CD14, likely representing previously de-
scribed monocytes with endothelial-like functional capac-
ity. (E) T-cell–depleted PBMCs were stained with FITC-
conjugated anti-CD14, PC5-conjugated anti-CD16, and
PE-conjugated anti-TIE2 or isotype control antibodies.
Expression of CD14 and CD16 (dot plot on the left)
identifies 2 distinct monocyte subsets (see text). The
gated cell populations (stained in different colors) were
analyzed for expression of TIE2 (top right dot plots)
versus isotype control (bottom right dot plots). Note that
the CD14lowCD16 fraction (resident monocytes; red
dots) is highly enriched in TIE2 cells, whereas the
CD14highCD16 fraction (inflammatory monocytes; violet
dots) contains few TIE2 cells. CD14 cells (blue and
pink dots) mainly represent B and natural killer cells and
are mostly TIE2. Representative analysis of at least 6
experiments performed on different donors. (F) The 2
main monocyte subsets were sorted from PBMCs using
the indicated gates (dot plot on the left) and reanalyzed
for expression of CD14, CD16, and TIE2 (dot plots on the
right) and after cytospin and May-Gru¨nwald-Giemsa
staining.
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likely represents monocytes or immature macrophages. Compared with
the blood TEMs, the average expression level of TIE2 appeared
substantially higher in the TIE2 tumor-infiltrating monocytes. Two
representative examples of these analyses are illustrated in Figure 4C-D,
which shows that 4% and 6% of the CD45 leukocytes and 55% and
70% of the CD14 monocytes were TIE2 in a colorectal (Figure 4C)
and a lung (Figure 4D) carcinoma, respectively. Of note, in both tumors
the wide majority of tumor-infiltrating CD45 leukocytes, which may
comprise TAMs, lymphocytes, and granulocytes, were TIE2.
Intriguingly, the frequency of TIE2CD45 cells was significantly
lower or undetectable in nonneoplastic tissues adjacent to the
tumors. As expected, normal tissues had a lower overall content of
CD45 hematopoietic cells than the tumors.
TIE2 immunostaining of cryostatic sections of cancer speci-
mens (Table S1) showed, in addition to robust and near-uniform
marking of blood vessels, the presence of scattered TIE2 mono-
nuclear cells within the tumor stroma (Figure 5). These cells
appeared distinct from ECs because they did not show connection
to blood vessels, had monocytic features (ie, roundish cytoplasmic
outline and small nuclei), and showed uniform staining by anti-
TIE2 antibodies lining the cell surface. Note that this type of
single-marker analysis could not identify TIE2 monocytes closely
associated with TIE2 blood vessels. Consistent with the flow-
cytometry data, the frequency of the TIE2 mononuclear cells was
low albeit variable among different tumor specimens, with some
tumors displaying minimal infiltration and others showing focal
increase of TIE2 cells. The vast majority of tumor-infiltrating
hematopoietic cells, including TAMs, were TIE2, ruling out
Fc-dependent binding of the antibody to macrophages.
In order to confirm the hematopoietic, nonendothelial nature of
the TIE2 mononuclear cells, we performed triple immunofluores-
cence staining and confocal microscopy on selected frozen sections
obtained from different tumor specimens (n  8; Figure 6). Vascu-
lar ECs were clearly identified by their morphology, their organiza-
tion in tubular structures, and the coexpression of TIE2 and CD31,
CD34 (not shown), or von Willebrand factor (VWF). Scattered
TIE2 cells distinct from ECs (CD31 or CD34 or VWF)
were frequently observed that coexpressed the hematopoietic
marker CD45. These cells had a small, rounded shape consistent
with the morphology of monocytes and expressed the myeloid
markers CD14, CD16, CD13 (not shown), and CD11b. These
TIE2 monocytes were often found in well-vascularized tumor
regions and sometimes had a peri-endothelial location (Figure
6F). Whereas the majority of CD14 monocytes were TIE2,
only a minority of the total CD45 hematopoietic cells ex-
pressed TIE2, indicating that TIE2 was a distinguishing feature
of tumor-infiltrating monocytes and was not expressed by the
wide majority of TAMs.
In agreement with flow analysis, we found that the nonneo-
plastic tissues adjacent to the tumors contained only a few
TIE2 hematopoietic cells (Figure 6G). Moreover, in normal
tissues obtained from surgery, we found that TIE2 expression
was restricted to ECs, even in organs heavily infiltrated by
hematopoietic lineage cells, such as the tonsils (Figure 6G).
Taken together, these findings indicated that human tumors selec-
tively recruit a population of TIE2-expressing CD14 monocytes
distinct from common macrophages (TAMs) and reminiscent of
mouse TEMs.15
Figure 3. Characterization of the TIE2 monocytes. (A) TIE2 cells
in unfractioned PBMCs were gated and analyzed for the expression of
a panel of hematopoietic markers, as indicated in the histogram plots.
The red open line shows expression of the indicated marker in the
gated TIE2 population (with the percentage of marker-positive cells
in red); the filled line depicts expression of the indicated marker in the
TIE2 cell population (with the percentage of marker-positive cells in
black). The TIE2 cells were CD45, CD11b, CD11c, CD16,
CD33, CD115, and CD13, which are all markers of monocytic
cells. In addition, the TIE2 cells were CCR2, CD62L (L-selectin),
and CCR5, a surface profile previously associated with resident
monocytes. As expected, the TIE2 cells were CD56, CD3, and
CD19 and thus distinct from natural killer cells and T and B
lymphocytes. Representative analysis of 3 to 6 experiments per-
formed on different donors.
Figure 2. TIE2 receptor expression by TIE2 monocytes. (A) TaqMan analyses of
TIE2 and VEGFR2 transcripts in FACS-sorted monocyte subsets showing Ct values
over endogenous control GAPDH. The lower the Ct, the higher the expression of the
transcript in the target cell population. Ct values are expressed as mean standard
error. Note that TIE2 transcript is clearly expressed in CD14lowCD16 (14low16)
resident but nearly undetectable in CD14CD16 (14  16) inflammatory mono-
cytes. (B) Relative quantification values of TIE2 transcript in FACS-sorted monocyte
subsets. TIE2 transcript is significantly enriched in CD14TIE2 (14TIE2) TEMs
compared with the resident monocytes. For each relative value, an interval of
confidence was calculated; confidence intervals that do not overlap indicate statisti-
cally significant differences (P 	 .05). (C) Western-blot analysis of TIE2 protein
expression in the indicated cell populations. Blots were probed with C-terminus
specific anti-TIE2 rabbit (top panels) or mouse anti-
 actin (bottom panels) antibod-
ies. The expected migration of each protein relative to molecular weight standards is
indicated. Representative experiment of 3 performed. (D) TIE2 immunoprecipitated
from CD14lowCD16 resident monocytes is phosphorylated on tyrosine. Representa-
tive experiment of 2 performed.
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Angiopoietin-2 exerts chemotactic activity on
TIE2-expressing monocytes
Ang-1 and Ang-2 stimulate vascular morphogenesis and shape
adult angiogenesis by promoting EC chemotaxis, survival, and/or
apoptosis in a context-dependent manner and in cooperation with
other angiogenic factors. We then investigated whether Tie2
expressed by monocytes could impart similar biologic responses
also to these cells. Previous studies showed that Ang-2 stimulated
the migration of blood-derived endothelial-like cells more effi-
ciently than Ang-1.36 Using a modified Boyden chamber assay, we
analyzed cell migration in response to an Ang-2 gradient. We
isolated resident monocytes, which are enriched in TEMs, and
inflammatory monocytes by magnetic sorting (see Cell purification
and cell sorting in Materials and methods and Figure S1). As shown
in Figure 7A, both serum and Ang-2 induced significant migration
of resident monocytes (P 	 .05 vs control medium), with the
higher response to an Ang-2 concentration of 100 ng/mL. Con-
versely, Ang-2 showed no significant chemotactic activity on
inflammatory monocytes (data not shown). To verify that the
chemotactic response observed was promoted by the specific
interaction between Ang-2 and TIE2, the cells were pretreated with
neutralizing anti-TIE2 antibodies. Anti-TIE2 antibodies, but not
control immunoglobulins, significantly blocked Ang-2–induced
cell migration. Of note, heat inactivation of Ang-2 abolished its
chemotactic activity. Together, these results strongly suggest that
TIE2 expressed on monocytes mediated their migration in response
to Ang-2.
TIE2-expressing monocytes are proangiogenic
We previously showed that mouse TEMs promote angiogenesis.15
To investigate whether human TIE2 monocytes have proangio-
genic activity, we isolated CD14TIE2 and CD14TIE2 cells
from human PB by cell sorting and coinjected these cells in
increasing ratios (1:100 and 1:20) with U87 human glioma cells
subcutaneously in nude mice. As controls, we injected U87 cells
alone and U87 cells together with unfractionated CD14 mono-
cytes, which mostly comprise inflammatory monocytes. We stud-
ied tumor vascularization 5 or 7 days after injection, when tumors
were at an early stage of growth (Figure 7B).
Figure 5. TIE2 immunohistochemistry of human cancer cryosections. After TIE2
immunostaining, the sections were counterstained with hematoxylin and eosin and
shown at lower (left) or higher (right) magnification. (A) Colon adenocarcinoma. In
addition to vascular ECs (arrowheads), TIE2 staining highlights the presence of
stromal mononuclear elements morphologically consistent with monocytes (arrows).
These cells appear inhomogeneously distributed, with foci of high density (arrows).
(B) Gastric undifferentiated adenocarcinoma. Many TIE2 mononuclear cells are
found in the tumor stroma (arrows). Blood vessels are indicated by arrowheads. (C)
Pancreatic adenocarcinoma. The majority of TIE2 structures in the left panel are
blood vessels (arrowheads). An individual TIE2 mononuclear cell is shown (arrow)
in the right panel.
Figure 4. TIE2 monocytes are found in human tumors. Flow cytometry analysis
of the indicated tumor specimens, processed and analyzed as described in the text.
FITC-conjugated anti-CD31 or anti-CD14, PE-conjugated anti-TIE2, or APC-
conjugated anti-CD45 antibodies were used. (A) Breast carcinoma. Note that the
gated CD31CD45 tumor-derived ECs are TIE2 (red open line in the histogram on
the right; filled line is the IgG isotype control). (B) Renal carcinoma. In this tumor
specimen, approximately 2% of the tumor-derived cells are CD31 (CD45, not
depicted) ECs. The wide majority of these CD31 tumor-derived ECs are TIE2. Note
that a fraction of the tumor-derived cells are CD31TIE2 non-ECs (top right dot plot).
In the same tumor sample, approximately 10% of tumor-derived cells are CD45
hematopoietic cells. Only a minor fraction (12%) of these CD45 cells are TIE2
(bottom right dot plot). (C) Colon carcinoma (left) and nonneoplastic colon mucosa
(right). In the tumor, 4% of the abundant CD45 hematopoietic cells and most of the
CD14 monocytes are TIE2. In the normal mucosa, CD45 hematopoietic cells are
much less abundant than in the tumor, and only a few TIE2 cells are found. Note that
CD14 monocytes are not detected in the normal mucosa. (D) Lung adenocarcinoma
(left) and nonneoplastic lung tissue (right). In the tumor, more than 30% of the cells
are CD45 hematopoietic cells, of which 6% are TIE2. Most of the tumor-derived
CD14 monocytes are TIE2. In the normal lung tissue, the CD45 hematopoietic
cells are TIE2; note that CD14 monocytes are not found in this tissue.
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In tumors derived from the injection of U87 cells alone (n  6),
CD31 blood vessels were exceedingly scarce within the inner
tumor mass, whereas few large blood vessels, likely sequestered
from the subcutaneous space, surrounded the tumors (Figure S2).
This finding indicates that angiogenesis had not yet started at this
early time of tumor growth. On the contrary, tumors coinjected
with human CD14TIE2 monocytes (n  6) were larger and
much more vascularized, with a profuse vascular framework
appreciably extending from the tumor periphery toward the inner
mass. In these tumors, blood vessels had the typical morphology of
angiogenic vessels (Figure 7B). In tumors coinjected with unfrac-
tioned CD14 (n  6) or CD14TIE2 monocytes (n  6), a small
rim of blood vessel ingrowths lined the tumor periphery, but only a
few spots of angiogenic vessels were observed within the inner
mass. Computer-assisted digital image analysis27 showed that the
overall vascular area was significantly greater in tumors coinjected
with CD14TIE2 monocytes than in control tumors and tumors
coinjected with unfractioned or TIE2 monocyte-depleted CD14
Figure 6. Confocal immunofluorescence analysis of
human cancer sections confirms the presence of
TIE2CD45CD14 tumor-infiltrating monocytes.
(A) Colon adenocarcinoma analyzed for CD31 (green),
TIE2 (red), and CD45 (blue). Confocal planes are
shown individually and after merging. Several
TIE2CD45CD31 hematopoietic cells (merge of red
and blue giving purple; arrows) are found within the tumor
stroma. Note that TIE2 is expressed by vascular ECs
(merge of green and red giving yellow; arrowheads),
which are TIE2CD45CD31. (B) Gastric adenocarci-
noma analyzed for CD31 (green), TIE2 (red), and CD45
(blue). Some TIE2CD45CD31 hematopoietic cells
are found in the tumor stroma (arrows) together with
TIE2CD45CD31 tumor blood vessels (arrowhead).
Scale bars as indicated. (C) Colon adenocarcinoma
analyzed for CD14 (green), TIE2 (red), and CD11b (blue).
Several TIE2CD14CD11b monocytes (arrows) are
found within the tumor stroma. Note TIE2 expression
by TIE2CD14CD11b vascular ECs (arrowheads).
(D) Gastric adenocarcinoma analyzed for VWF (green),
TIE2 (red), and CD11b (blue). Arrowheads indicate
TIE2CD11bVWF monocytes. (E) Pancreatic adeno-
carcinoma analyzed for CD16 (green), TIE2 (red), and
CD14 (blue). High-magnification photos show the pres-
ence of TIE2CD16CD14 monocytes (arrows) in the
tumor stroma. (F) Colon adenocarcinoma analyzed for
CD14 (green), TIE2 (red), and CD11b (blue). A triple-
positive CD14TIE2CD11b TEM with peri-endothelial
localization is indicated by the arrow. Note the presence
of CD14TIE2CD11b inflammatory cells (arrowheads).
Scale bars as indicated. (G) TIE2 expression in nonneo-
plastic tissues is restricted to vascular ECs. Nonneoplas-
tic colon mucosa adjacent to tumor tissue analyzed by
confocal immunofluorescence staining of CD31 or CD14
(green), TIE2 (red), and CD45 (blue). Note that the
lamina propria macrophages are CD14TIE2. A single
CD14TIE2 monocyte (arrow) is found within a TIE2
blood vessel. Tonsil sections show that TIE2 expression
(red) is restricted to CD31 vascular ECs (green). CD19
B cells are stained in blue. Scale bars as indicated.
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cells at both cell ratios (Figure 7C). These results indicated that,
among human blood monocytes, the CD14TIE2 subset was
specifically endowed with the ability to enhance angiogenesis in a
tumor transplantation model.
Discussion
It has been proposed that tumor-infiltrating innate immune cells are
more likely to contribute to tumor progression than they are to
mount an effective host antitumor response.1,2,5 Among inflamma-
tory cells found in tumors, TAMs and mast cells are thought to
support tumor growth and neovascularization by producing a wide
array of growth and proangiogenic factors. Many of these mol-
ecules can be up-regulated in macrophages by tumor-secreted
factors and by hypoxia, which is a hallmark of cancer.10 More
recently, hematopoietic cells phenotypically distinct from TAMs
have been implicated in tumor angiogenesis.7,15,17,20-26 In some
studies, the impaired recruitment of such hematopoietic popula-
tions was sufficient to restrict tumor angiogenesis and growth,
suggesting that the predominant proangiogenic activity of hemato-
poietic cells in experimental tumors might be attributed to yet
poorly characterized myeloid subpopulations rather than
TAMs.15,17,20,21,24
In our previous studies, we showed that proangiogenic
Tie2-expressing monocytes are recruited to mouse tumors,
where they constitute a small fraction of the total CD11b
tumor-infiltrating myeloid cells. Because TEMs isolated from
PB were proangiogenic, we proposed the notion that TEMs
may have inherent vascular growth–promoting activity, thus
representing a circulating reservoir of cells committed to a
proangiogenic function.15 In this work, we describe a novel
subset of proangiogenic monocytes found in human PB and
tumors. These cells express a unique combination of cell-surface
markers (TIE2CD14lowCD16CCR2L-selectin), which distin-
guishes them from common inflammatory monocytes.14 The pheno-
type and proangiogenic activity of human TEMs (TEMs) are
reminiscent of those of previously described murine TEMs.15
However, the substantial lack of surface markers shared by human
and mouse monocytes, together with the paucity and elusive
phenotype of monocytes in mice, make it difficult to ascertain
whether the TIE2 cells that we identified in PB (this study and De
Palma et al15) represent the same cell type in humans and mice.
Moreover, the lack of monocyte- and macrophage-specific markers
in mice prevented us from accurately defining the phenotype of
TEMs, which could be distinguished from common TAMs only
based on Tie2 expression.
Here, we show that TEMs are distinct from TAMs according to
their surface-marker profile, which conversely overlaps with that of
resident monocytes, a population of immature monocytes believed
to represent precursors of tissue macrophages.14 Remarkably, we
found that TEMs were recruited to human carcinomas and soft-
tissue sarcomas and specifically promoted angiogenesis in experi-
mental tumors in vivo, indicating a novel and unexpected role for
resident monocytes in tumor angiogenesis. Of note, only a fraction
of the circulating resident monocytes expressed TIE2, suggesting
that a certain degree of phenotypical and functional heterogeneity
exists within the resident monocyte subset. Interestingly, our
studies showed that inflammatory monocytes, which represent the
major monocyte population in PB and are believed to represent the
precursors of TAMs, were less proangiogenic than TEMs in vivo.
A peculiar feature of TEMs is that they preferentially localize in
the proximity of tumor blood vessels, which is consistent with their
proangiogenic activity in transplantation assays (this study and De
Palma et al15). However, the molecular bases of the proangiogenic
activity of TEMs and the factors that recruit these cells to tumors
remain to be investigated. Circulating TEMs did not express
L-selectin (CD62L), a member of the selectin family of adhesion
molecules that facilitate rolling of inflammatory leukocytes along
the vascular endothelium, or CCR2, the receptor for MCP-1
(monocyte chemoattractant protein-1, also known as CCL2), a
chemokine involved in the recruitment of inflammatory monocytes
to tumors and experimentally induced inflammation. Although we
did not investigate recruitment of TEMs to inflammatory disease,
their L-selectinCCR2 phenotype should exclude them from
inflamed tissues. In this regard, recruitment of proangiogenic
myeloid cells to tissues harboring an inducible VEGF transgene has
been shown to occur in the absence of inflammatory stimuli.25
Thus, noninflammatory circuits may govern the recruitment of
TEMs to tumors. It is tempting to speculate that TEMs may use
selected tumor-secreted, noninflammatory mediators to specifically
home to tumors, even at early stages of tumor progression, a feature
that would distinguish these cells form other tumor-infiltrating
Figure 7. Circulating TIE2 monocytes migrate toward Ang-2 and have marked
proangiogenic activity in vivo. (A) Modified Boyden chamber assays show
migration of resident monocytes toward Ang-2. The 2 graphics show parts of 2
independent experiments of 3 performed. Both serum and Ang-2 induced significant
migration of resident monocytes (left histograms; P 	 .05 vs control: Medium). Heat
inactivation of Ang-2 or treatment of the cells with neutralizing anti-TIE2 antibodies,
but not with control immunoglobulins, abrogates cell migration in response to Ang-2
(right histograms). (B) Human glioma U87 cells were injected subcutaneously into
nude mice with or without the indicated monocyte populations at a 1:100 or 1:20 ratio.
Tumors were grown for 5 to 7 days and analyzed by CD31 immunostaining and
confocal analysis to assess angiogenesis. Representative pictures of the tumors are
shown. The tumor margin is indicated by a dashed line. (C) The mean vascular area
(n  3 tumors/group) was calculated by digital image analysis and expressed as fold
increase over the value obtained in tumors from U87 cells only. Error bars indicate
SD. Statistical difference between groups was calculated by Student t test.
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hematopoietic populations, such as TAMs, which are prototypical
cellular components of the inflammatory network in established
tumors. According to this hypothesis, TEMs may be attracted to yet
avascular and noninflamed tumor areas in a CCR2-independent
manner, where they would promote the angiogenic process. The
tumor-homing specificity of TEMs could be mediated by signals
that are produced by the cancer cells or stromal components of
tumors, including activated myofibroblasts37 and ECs.38 Peri-
tumoral blood vessels may indeed express selected adhesion
molecule and chemoattractant factors for monocytes.39-41 Among
these factors, angiopoietins may have a crucial role. We demon-
strated that TEMs directly respond to Ang-2 and that the TIE2
receptor is involved in this response. Expression of Ang-2, which is
stored in Weibel-Palade bodies in ECs and rapidly released from
them upon EC activation,42,43 is indeed up-regulated by tumor
hypoxia and may function as a chemoattractant for TIE2 mono-
cytes. Intriguingly, we showed that TIE2 expression was up-
regulated in tumor-infiltrating TEMs, which is consistent with the
reported up-regulation of this receptor in ECs at angiogenic and
hypoxic sites44,45 and suggests the occurrence of a positive
feedback loop reinforcing TEM recruitment at these sites.
We did not observe TEMs in normal, nonneoplastic tissues,
suggesting that they may represent a specific subset of resident
monocytes distinct from the precursors of tissue macrophages. It is
conceivable, although experimental evidence in this direction is
still lacking, that resident monocytes can be further divided into
subsets endowed with tissue or organ specificity,14 including
tropism for neoangiogenic sites, such as growing and regenerating
tissues, wounds, and tumors. Because proangiogenic TEMs circu-
late in PB at steady state, they may have a constitutive role in
supporting tissue growth and regeneration, as we previously noted
in hepatectomized mice.17 It is also possible, however, that a slow
turnover of tissue resident macrophages prevented us from detect-
ing a role of TEMs as precursors of macrophages in the organs
analyzed, and further studies are thereafter required.
Although TIE2 should also be expressed by rare CECs and
EPCs, TEMs can be easily distinguished from CECs/EPCs because
the latter cells do not express hematopoietic markers. However, in
agreement with a recent study,31 we noted that a very small
percentage of TIE2 monocytes also expressed VEGFR-2, an
endothelial-specific receptor commonly used to identify CECs/
EPCs. Although our analyses showed that greater than 95% of the
CD14TIE2 cells were VEGFR-2, we cannot formally rule out
that a certain degree of heterogeneity may exist in the “TEM”
population and that minor cell subsets copurifying with TEMs
might contribute to some of the biologic activities observed. Kerbel
and colleagues (Mancuso et al29 and Shaked et al46) have proposed
that the frequency of CECs/EPCs in PB may serve as a pharmaco-
dynamic surrogate marker to monitor the magnitude of angiogen-
esis and the effectiveness of antiangiogenic therapy. It will be
worth investigating whether TEMs are reproducibly increased in
cancer patients according to the type and stage of the disease and in
other pathologic conditions characterized by dysregulated angiogen-
esis. In such a circumstance, TEMs could provide a novel, robust,
and biologically relevant marker to monitor angiogenesis.
The identification of TEMs opens a number of avenues to the
development of both antiangiogenic and proangiogenic therapy.
TEMs may represent unrecognized targets of cytoablative treat-
ments, which may restrict tumor growth not only by targeting
cancer cells but also by suppressing myelopoiesis and, conse-
quently, impairing the generation and function of proangiogenic
monocytes.47 The identification of TEM-specific genes will provide
candidate molecular targets for the development of new and safer
antiangiogenic therapy. On a different perspective, TEMs could be
administered or recruited to ischemic sites to promote angiogenesis
and improve organ function.
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